The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Endocannabinoids control spasticity in a multiple sclerosis model
Abstract
Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2‐arachidonoyl glycerol (2‐AG), and of the AEA congener, palmitoylethanolamide (PEA), were detected here, whereas comparable levels of these compounds were found in normal and non‐spastic CREAE mice. While exogenously administered endocannabinoids and PEA ameliorate spasticity, selective inhibitors of endocannabinoid re‐uptake and hydrolysis—probably through the enhancement of endogenous levels of AEA, and, possibly, 2‐arachidonoyl glycerol—significantly ameliorated spasticity to an extent comparable with that observed previously with potent cannabinoid receptor agonists. These studies provide definitive evidence for the tonic control of spasticity by the endocannabinoid system and open new horizons to therapy of multiple sclerosis, and other neuromuscular diseases, based on agents modulating endocannabinoid levels and action, which exhibit little psychotropic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142 · cited 2×
“Further, studies are also warranted to evaluate whether the levels of functional receptors for endocannabinoids [to date, AEA has been found to bind to the two CB receptors, as well as to vanilloid receptors] (2, 18 , 19) are likewise changed from the non-spastic condition to compensate for the effects of the disease.”
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Self-citationDopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
Self-citationCannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 532
Self-citationPharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Self-citationElevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
Mechoulam, R., Fride, E., & Di Marzo, V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00649-9 · Cited by 428
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Self-citation(R)-Methanandamide: A Chiral Novel Anandamide Possessing Higher Potency and Metabolic Stability
Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G., & Makriyannis, A. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00038a020 · Cited by 346
Self-citationThe antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
Sommer, N., Löschmann, P.-A., Northoff, G. H., Weller, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmüller, A., Fontana, A., et al. (1995) · Nature Medicine · doi:10.1038/nm0395-244 · Cited by 345
Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand
Goparaju, S. K., Ueda, N., Yamaguchi, H., & Yamamoto, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01603-7 · Cited by 328
Felder, C. C., Nielsen, A., Briley, E. M., Palkovits, M., Priller, J., Axelrod, J., Nguyen, D. N., Richardson, J. M., Riggin, R. M., Koppel, G. A., et al. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00891-5 · Cited by 326
Bisogno, T., Berrendero, F., Ambrosino, G., Cebeira, M., Ramos, J. A., Fernandez-Ruiz, J. J., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0254 · Cited by 312
Self-citationdi Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303
Self-citationBISOGNO, T., SEPE, N., MELCK, D., MAURELLI, S., PETROCELLIS, L. D., & MARZO, V. D. (1997) · Biochemical Journal · doi:10.1042/bj3220671 · Cited by 275
Self-citationIntravesical capsaicin for neurogenic bladder dysfunction
Fowler, C., Jewkes, D., Ian Mcdonald, W., Lynn, B., & De Groat, W. C. (1992) · The Lancet · doi:10.1016/0140-6736(92)91186-c · Cited by 228
Pertwee, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1553 · Cited by 208
Self-citationMARZO, V. D., BISOGNO, T., SUGIURA, T., MELCK, D., & PETROCELLIS, L. D. (1998) · Biochemical Journal · doi:10.1042/bj3310015 · Cited by 199
Self-citationInduction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice
Baker, D., O'Neill, J. K., Gschmeissner, S. E., Wilcox, C. E., Butter, C., & Turk, J. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90019-j · Cited by 192
Self-citationAnandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide
Maccarrone, M., Bari, M., Lorenzon, T., Bisogno, T., Di Marzo, V., & Finazzi-Agrò, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13484 · Cited by 184
Self-citationEndocannabinoids and fatty acid amides in cancer, inflammation and related disorders
De Petrocellis, L., Melck, D., Bisogno, T., & Di Marzo, V. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00196-1 · Cited by 173
Self-citationDi Marzo, V., Berrendero, F., Bisogno, T., González, S., Cavaliere, P., Romero, J., Cebeira, M., Ramos, J. A., & Fernández‐Ruiz, J. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741627.x · Cited by 168
Self-citationFatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor
Deutsch, D. G., Lin, S., Hill, W. A. G., Morse, K. L., Salehani, D., Arreaza, G., Omeir, R. L., & Makriyannis, A. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6072 · Cited by 134
Self-citationBrain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
Consroe, P. F. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0220 · Cited by 133
Anandamide: an endogenous activator of the vanilloid receptor
Smart, D., & Jerman, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01459-0 · Cited by 120
Gifford, A. N., Bruneus, M., Lin, S., Goutopoulos, A., Makriyannis, A., Volkow, N. D., & Gatley, S. J. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00609-3 · Cited by 57
Self-citationAnandamide, an Endogenous Cannabinoid, Has a Very Low Physical Dependence Potential
Aceto, M. D. G., Scates, S. M., Razdan, R. K., & Martin, B. R. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37833-4 · Cited by 54
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Lyman et al. (1989) examined the effects of parenteral THC in experimental autoimmune encephalomyelitis (EAE) in rats, a laboratory model of MS. THC treatment not only reduced CNS inflammation and improved neurological outcome but also improved survival compared with placebo.”
BackgroundInfluentialPharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Self-citationCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Self-citation
Metadata
- Authors
- Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Makriyannis, A., Khanolkar, A., Layward, L., Fezza, F., Bisogno, T., & Marzo, V. D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2000-12-08
- Volume
- 15
- Issue
- 2
- Pages
- 300-302
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2113319670
- Cited by
- 378
- References
- 29
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.